Hospital Universitari Joan XXIII De Tarragona

At Hospital Universitari Joan XXIII De Tarragona, clinical trials in infectious diseases focus on improving care for severe bacterial pneumonia, HIV, and recurrent urinary tract infections. The studies are designed to test new treatment approaches, support infection control, and reduce the burden of resistant or difficult-to-treat infections.

• Severe community-acquired bacterial pneumonia: evaluating a new supportive therapy alongside standard care
• HIV: comparing maintenance treatments to preserve viral suppression
• Recurrent urinary tract infections: assessing a non-antibiotic prevention strategy

This research reflects a strong interest in practical solutions that may improve recovery, limit recurrence, and help preserve treatment options for patients.

The site is actively involved in hematology and oncology trials centered on acute myeloid leukemia, multiple myeloma, and myelodysplastic syndrome. These studies aim to improve remission rates, clear residual disease, and extend survival through better treatment combinations.

• Acute myeloid leukemia: testing new combinations to improve response and disease control
• Multiple myeloma: comparing treatment strategies for newly diagnosed patients
• Myelodysplastic syndrome: studying regimens intended to strengthen treatment effectiveness

This area highlights a clear focus on more precise and effective therapies for blood cancers, especially in patients who need better long-term disease control.

Cardiovascular trials at this Spanish hospital cover myocardial infarction, heart failure, hypertension, spontaneous coronary artery dissection, and broader atherosclerotic cardiovascular disease. The main goal is to evaluate treatments that may lower major cardiovascular events, improve recovery after acute heart injury, and optimize long-term risk management.

• Acute myocardial infarction: testing therapies to reduce future cardiovascular complications
• Heart failure and hypertension: assessing approaches that may improve symptoms and outcomes
• Spontaneous coronary artery dissection: studying standard medical therapy in a rare heart condition

These trials show a broad effort to address both urgent cardiac events and chronic vascular risk with more effective, patient-centered care.

Research in neurological diseases includes studies in acute ischemic stroke, intracerebral hemorrhage, and traumatic brain injury. The trials are aimed at improving functional recovery, reducing complications, and refining treatment choices in time-sensitive brain conditions.

• Acute ischemic stroke: evaluating strategies to support better recovery after thrombectomy
• Intracerebral hemorrhage: testing treatments that may improve outcomes after brain bleeding
• Traumatic brain injury: assessing safety and tolerability of a novel intranasal therapy

This portfolio emphasizes urgent neurological care, where even modest improvements in treatment can have a major impact on independence and quality of life.

Clinical research in respiratory disease, critical care, and anesthesia addresses acute respiratory distress syndrome, mechanical ventilation support, and sedation strategies in critically ill patients. The purpose is to improve recovery in severe illness and make intensive care treatment safer and more effective.

• ARDS due to infection: testing a therapy intended to support clinical recovery
• Mechanical ventilation and sedation: comparing inhaled and intravenous sedation approaches
• Critical illness: evaluating interventions that may improve short-term outcomes and stabilization

These studies reflect a strong intensive care focus, with attention to both survival and the quality of recovery during hospitalization.

Trials in immune system diseases, allergy, and kidney disease explore allergic rhinoconjunctivitis, immunoglobulin A nephropathy, and related inflammatory conditions. The research is designed to improve symptom control, protect organ function, and evaluate more targeted treatment options.

• Allergic rhinoconjunctivitis: studying immunotherapy to reduce allergic symptoms
• Immunoglobulin A nephropathy: assessing treatment effects on kidney damage and function
• Immune-mediated conditions: exploring therapies that may better control inflammation

This area combines allergy and renal research with a common aim of reducing disease activity while preserving long-term health.

Research also extends to nutritional and metabolic diseases and pregnancy-related conditions, including metabolic associated fatty liver disease, severe hypertriglyceridemia, and preeclampsia. These trials aim to improve prevention, reduce complications, and support safer care for both adults and pregnant patients.

• Fatty liver disease and prediabetes: evaluating approaches to reduce liver fat and metabolic risk
• Severe hypertriglyceridemia: testing a therapy to lower high triglyceride levels
• Preeclampsia prevention: studying whether adjusted aspirin use can help reduce risk

The work in this field reflects a preventive approach, targeting metabolic imbalance and pregnancy complications before they lead to more serious outcomes.